uniQure price target lowered to $50 from $70 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on uniQure (QURE) to $50 from $70 and keeps a Buy rating on the shares after the company reported Q1 results and provided updates across its gene therapy pipeline. AMT-130 timing risk has increased in the U.S., but the U.K. path “now provides a credible route to first approval” and the firm continues to view AMT-130 as having “the strongest clinical dataset generated” in Huntington’s disease, the analyst tells investors.